FDA clears Berlex Laboratories Mirena (R), new form of long-acting contraception meets need for U.S. women

Montville, NJ, December 6, 2000 Berlex Laboratories, Inc., the U.S. subsidiary of Schering AG, Germany (NYSE: SHR), announced today that the U.S. Food and Drug Administration (FDA) approved MIRENA(R) (levonorgestrel-releasing intrauterine system), a convenient, innovative contraceptive that is as effective in preventing pregnancy as tubal ligation (better than 99 percent) and lasts for five years, or until removed.

Available for 10 years in Europe, MIRENA has been used by approximately two million women worldwide and will be available for the first time in the U.S. in the first quarter of 2001. "Women in European and Asian countries have used MIRENA successfully and safely." says Felicia Stewart, MD, Incoming Chair of the Association of Reproductive Health Professionals. "For many women in the U.S. there has been a limited choice in convenient, reliable and reversible long-acting contraception. MIRENAs availability gives these women a choice they need and deserve."

In addition to preventing pregnancy, MIRENA use may result in a change in bleeding patterns. In the first three to six months following insertion, there may be an increase in intermenstrual bleeding. After this, a womans period may become shorter and lighter. Some women experience an absence of menstrual bleeding after one year.

MIRENA does not contain estrogen. It delivers a low dose of the progestin levonorgestrel directly to the lining of the uterus. Studies suggest several mechanisms that prevent pregnancy: thickening of cervical mucus, which prevents the passage of sperm, inhibition of sperm mobility and inhibition of endometrial growth. Berlex will market MIRENA under a license from The Population Council, which initially developed the contraceptive.

"MIRENA is the first in a series of major new products that Berlex will bring to market, and its introduction marks the beginning of an expansion in the Berlex position in women's health," said Reinhard Franzen, Vice

Contact: Julie Mandell
Porter Novelli

Page: 1 2 3

Related biology news :

1. Wildland fires: After the smoke clears
2. FDA clears for market new diagnostic test for lupus
3. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin
4. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
5. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
6. Study finds two-thirds of unplanned pregnancies in women using contraception
7. Proteins that bind to sperm offer clues to male fertility and possible male contraception
8. Chemistry meets Biology
9. The American Society for Biochemistry and Molecular Biology meets in Boston
10. Experimental Biology 2004 meets in Washington, D.C. April 17-21
11. Experimental Biology 2003 meets in San Diego April 11-15

Post Your Comments:

(Date:1/23/2020)... ... 23, 2020 , ... GIOSTAR/HEAMGEN has developed and ... The red blood cells are made utilizing a bioreactor that permits the ... and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature ...
(Date:1/22/2020)... MESA, Calif. (PRWEB) , ... January 21, 2020 ... ... of Robert Pozil to lead the company’s new Business Development Department. The move, ... 2019. Mr. Pozil had been previously serving as the company’s Senior Vice President ...
(Date:1/10/2020)... ... January 09, 2020 , ... Cutting Edge Spine, a leader ... clearance and commercial launch of the latest addition to its bioactive portfolio of ... is made of PEEK-OPTIMA HA Enhanced material supplied by Invibio Biomaterial Solutions. Cutting ...
Breaking Biology News(10 mins):
(Date:1/7/2020)... (PRWEB) , ... January 06, 2020 , ... ... a Digital World at The Fletcher School at Tufts University, is pleased to ... Foundation. The grant will be administered by Tufts University, and will help to ...
(Date:1/7/2020)... ... 06, 2020 , ... ABCT , the Accelerator for ... to participate in the annual program. Twelve ventures will participate in the 6.5-month-long ... network. All startups will receive an entrepreneur coach, access to active business professionals ...
(Date:12/31/2019)... ... 2019 , ... At this year's SLAS conference, Visikol will present several talks ... 3D cell culture , advanced imaging and multiplex analysis . Specifically, ... steatosis , inflammation and fibrosis as well as a 2D cell culture ...
(Date:12/27/2019)... ... December 27, 2019 , ... Leak Detection ... for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries is excited to ... Following acquisition by CLJ Holdings in February, 2019, a comprehensive and aggressive reorganization ...
Breaking Biology Technology:
Cached News: